Showing results (221-230 of 300) with videos related to
Sort By:
Pageof 30
JNCI Cancer Spectrum|November 23, 2024
Trilaciclib prior to FOLFOXIRI/bevacizumab for patients with untreated metastatic colorectal cancer: phase 3 PRESERVE 1 trialHeinz-Josef Lenz, Tianshu Liu, Emerson Y Chen, et al.Quantitative Imaging in Medicine and Surgery|December 10, 2025
Automated and accurate view classification of fetal echocardiography using convolutional neural networksJiawei Shi, Ying Bai, Quanfei Hou, et al.Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|November 30, 2025
Targeting WEE1 in ARID1A/TP53 Concurrent Mutant Colorectal Cancer by Exploiting R-Loop Accumulation and DNA Repair DeficienciesChi Zhang, Yanjing Zhu, Luoyan Ai, et al.Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|March 1, 2018
A multicenter, randomized trial comparing efficacy and safety of paclitaxel/capecitabine and cisplatin/capecitabine in advanced gastric cancerZhihao Lu, Xiaotian Zhang, Wei Liu, et al.Journal of Hematology & Oncology|January 11, 2018
Correction to: Early presence of anti-angiogenesis-related adverse events as a potential biomarker of antitumor efficacy in metastatic gastric cancer patients treated with apatinib: a cohort studyXinyang Liu, Shukui Qin, Zhichao Wang, et al.Frontiers in Cardiovascular Medicine|August 7, 2025
First-phase ejection fraction is associated with myocardial fibrosis in the pressure overloaded heartShukun He, Jingrong Jiang, Yanting Zhang, et al.Journal of Hematology & Oncology|September 6, 2017
Early presence of anti-angiogenesis-related adverse events as a potential biomarker of antitumor efficacy in metastatic gastric cancer patients treated with apatinib: a cohort studyXinyang Liu, Shukui Qin, Zhichao Wang, et al.The Lancet. Gastroenterology & Hepatology|October 9, 2021
Efficacy and safety of weekly paclitaxel with or without ramucirumab as second-line therapy for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma (RAINBOW-Asia): a randomised, multicentre, double-blind, phase 3 trialRui-Hua Xu, Yanqiao Zhang, Hongming Pan, et al.Cancer Biology & Medicine|January 20, 2025
Retrospective analysis of disease characteristics and treatment patterns among patients with esophageal cancer across 14 surgically represented centersZhihao Lu, Mingfei Geng, Yongtao Han, et al.Oncogene|June 10, 2026
Targeting ATF3-mediated asparagine biosynthesis reverses acquired resistance to KRAS<sup>G12C</sup> inhibitorsYanjing Zhu, Chi Zhang, Min Li, et al.Pageof 30